Experiences from Labqualityʼs First Somatic NGS EQA Pilot Study

Next-generation sequencing (NGS) has become an essential technology in molecular pathology and precision oncology. Despite the increasing clinical use of NGS, external quality assessment (EQA) for comprehensive NGS workflows remains technically challenging due to the diversity of laboratory-used panels, bioinformatics pipelines, result interpretation practices and reporting formats. In 2026, Labquality launched its first pilot EQA scheme for NGS testing of somatic tumours as part of the development of a new genomics and molecular pathology EQA portfolio.